Consider Akynzeo for Highly Emetogenic Chemotherapy

February 2018

Akynzeo (ah-KIN-zee-oh) will be a new ORAL antiemetic combo to prevent chemotherapy-induced nausea and vomiting.

Akynzeo combines the 5-HT3 antagonist, palonosetron (Aloxi), with a new long-acting neurokinin-1 (NK-1) antagonist, netupitant. Think of netupitant as an alternative to aprepitant (Emend).

NK-1 antagonists boost the efficacy of 5-HT3 antagonists to prevent nausea and vomiting.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Diabetes Look for New GLP-1 Agonists for Type 2 Diabetes
Monitoring Compare FreeStyle Libre and Other Continuous Glucose Monitors
Women's Health Ease Fears About Breast Cancer Risk With Hormonal Contraception
Natural Health Products Be Aware That Biotin May Skew Lab Test Results
Natural Health Products Watch for Warnings of Liver Damage on Labels of Green Tea Extract Products
Cardiology Use "ABCDs" to Optimize Meds for Stable Coronary Artery Disease
Asthma Ensure Long-Acting Beta-Agonists Aren't Used Alone for Asthma
Travel Medicine Share Strategies to Limit Altitude Sickness
Psoriasis Know Key Points About Biologics for Your Patients With Psoriasis
Nausea & Vomiting Consider Akynzeo for Highly Emetogenic Chemotherapy
Practice Get Tools to Tackle This Flu Season
Practice Advise Patients That Using Expired EpiPen May Be Needed During the Shortage

Consider Akynzeo for Highly Emetogenic Chemotherapy

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents